Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• Ironwood beat quarterly estimates: Earnings were $0.36 per share versus the $0.32 consensus, and revenue of $133.04 million exceeded the $119.99 million estimate.
• LINZESS sales drove a stronger outlook: The drug posted record quarterly net sales of $325 million, and Ironwood raised its 2026 LINZESS sales guidance to $1.2 billion–$1.25 billion; management cautioned that pricing benefits may not continue beyond this year.
• Profitability and development progress: Ironwood reported record adjusted EBITDA of $98 million, paid down $60 million of debt, and said STARS-2 remains on track, with primary completion estimated for October 2028.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.04, FiscalAI reports. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. The business had revenue of $133.04 million during the quarter, compared to analyst estimates of $119.99 million.

Here are the key takeaways from Ironwood Pharmaceuticals' conference call:

• LINZESS had its strongest-ever quarterly net sales at $325 million, and Ironwood raised 2026 guidance to $1.2 billion–$1.25 billion, implying growth of more than 35%. Management cited improved net pricing and mid-single-digit prescription demand growth, while noting that pricing tailwinds may not persist beyond this year.
• Ironwood reported $98 million in record adjusted EBITDA and $60 million in GAAP net income for Q3. It paid down $60 million of debt during the quarter and expects year-end debt below $300 million, while funding apraglutide development.
• The company said STARS-2 site activation is on track, with more than 100 sites planned across 22 countries and activated sites recruiting patients. The estimated primary completion remains October 2028, supporting a potential 2029 NDA submission.
• CEO Tom McCourt plans to retire, with Chief Commercial Officer Tammy Gaskins set to become CEO on January 1, 2027. Management emphasized continuity, citing Gaskins’ role in LINZESS’s growth and the company’s turnaround.

Ironwood Pharmaceuticals Trading Up 8.9%

Shares of Ironwood Pharmaceuticals stock traded up $0.36 during mid-day trading on Friday, hitting $4.39. 3,963,094 shares of the stock were exchanged, compared to its average volume of 1,623,355. The stock has a market capitalization of $725.40 million, a price-to-earnings ratio of 4.44 and a beta of 0.25. The company has a 50-day simple moving average of $3.91 and a 200 day simple moving average of $3.97. Ironwood Pharmaceuticals has a twelve month low of $1.88 and a twelve month high of $5.78.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Weiss Ratings upgraded Ironwood Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Wall Street Zen cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 5th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Finally, Jefferies Financial Group upgraded shares of Ironwood Pharmaceuticals to a "hold" rating in a research note on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $6.23.

Key Stories Impacting Ironwood Pharmaceuticals

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
• Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood's principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.